Abstract
Highly active antiretroviral therapy is not sufficient to fully control HIV replication and problems of side effects and escape mutation have emerged. Current prophylactic and therapeutic vaccine strategies appear to be unable to confer full protection. However, given the rapid recent progress made in RNA interference and lentivirus technologies, it may soon be possible to develop effective gene therapies against HIV infection. We describe here the recent progress made in the lentivirus-based HIV-1-targeting RNAi system and the possibility that this system can be used to generate an anti-HIV-1 gene therapy. We speculate that this system would be most useful if it would be used in a coordinated manner with vaccines that can initiate and maintain potent anti-HIV immunity.
Keywords: RNAi, lentivirus vector, gene therapy, HIV infection, vaccines
Current Gene Therapy
Title: Prospects for the Therapeutic Application of Lentivirus-Based Gene Therapy to HIV-1 Infection
Volume: 8 Issue: 1
Author(s): Takuya Yamamoto and Yasuko Tsunetsugu-Yokota
Affiliation:
Keywords: RNAi, lentivirus vector, gene therapy, HIV infection, vaccines
Abstract: Highly active antiretroviral therapy is not sufficient to fully control HIV replication and problems of side effects and escape mutation have emerged. Current prophylactic and therapeutic vaccine strategies appear to be unable to confer full protection. However, given the rapid recent progress made in RNA interference and lentivirus technologies, it may soon be possible to develop effective gene therapies against HIV infection. We describe here the recent progress made in the lentivirus-based HIV-1-targeting RNAi system and the possibility that this system can be used to generate an anti-HIV-1 gene therapy. We speculate that this system would be most useful if it would be used in a coordinated manner with vaccines that can initiate and maintain potent anti-HIV immunity.
Export Options
About this article
Cite this article as:
Yamamoto Takuya and Tsunetsugu-Yokota Yasuko, Prospects for the Therapeutic Application of Lentivirus-Based Gene Therapy to HIV-1 Infection, Current Gene Therapy 2008; 8 (1) . https://dx.doi.org/10.2174/156652308783688536
DOI https://dx.doi.org/10.2174/156652308783688536 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Preface: Unraveling Natures Secrets, from Neurons and Memory to Brain Disorders: Exploring the New Frontier of Alzheimers Disease
Current Alzheimer Research Elevation of E-Selectin Concentrations may Correlate with Potential Endothelial Dysfunction in Individuals with Hypopituitarism During Therapy with Growth Hormone
Current Neurovascular Research Chitosan Nanoparticles: An Approbative System for the Delivery of Herbal Bioactives
The Natural Products Journal Leptin as a Novel Therapeutic Target for Immune Intervention
Current Drug Targets - Inflammation & Allergy Intraocular Inflammation and Systemic Immune-Mediated Diseases
Current Immunology Reviews (Discontinued) The Implications of Urine Drug Testing in Pain Management
Current Drug Safety A Review of the Efficacy and Cardiovascular Safety of Amylin Analogues
Current Drug Safety AIDS-Related Kaposis Sarcoma: State of the Art and Therapeutic Strategies
Current HIV Research Aspartame: Should Individuals with Type II Diabetes be Taking it?
Current Diabetes Reviews Hydroxamate, a Key Pharmacophore Exhibiting a Wide Range of Biological Activities
Mini-Reviews in Medicinal Chemistry Mitochondrial Targeting for Development of Novel Drug Strategies in Brain Injury
Central Nervous System Agents in Medicinal Chemistry Actions of Melatonin, Its Structural and Functional Analogs in the Central Nervous System and the Significance of Metabolism
Central Nervous System Agents in Medicinal Chemistry Receptor-Binding and Pharmacokinetic Properties of Dopaminergic Agonists
Current Topics in Medicinal Chemistry MYC-Mediated Synthetic Lethality for Treating Tumors
Current Cancer Drug Targets Prokinetic Agents and QT Prolongation: A Familiar Scene with New Actors
Current Drug Safety Prediction and Targeting of Interaction Interfaces in G-protein Coupled Receptor Oligomers
Current Topics in Medicinal Chemistry Effects of Acute and Repeated Administration of Methamphetamine on Aggression-Related Behavior During Adolescence in Male and Female Rats, and Subsequent Outcomes in Early Adulthood
Current Psychopharmacology Patent Selections
Recent Patents on CNS Drug Discovery (Discontinued) Toward a Developmentally Centered Approach to Adolescent Alcohol and Substance Use Treatment
Current Drug Abuse Reviews Neuroprotection by Association of Palmitoylethanolamide with Luteolin in Experimental Alzheimer’s Disease Models: The Control of Neuroinflammation
CNS & Neurological Disorders - Drug Targets